Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of colorectal cancer~* No prior chemotherapy and scheduled to receive FOLFOX chemotherapy (oxaliplatin,leucovorin and 5-fluorouracil)~* Age ≥18 years~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2~* Laboratory index: Hemoglobin ≥ 90 g/L (No blood transfusion within 14 days), Absolute Neutrophil Count ≥ 1.5×10\^9/L, Platelet Count ≥ 75×10\^9/L, Serum Bilirubin ≤ 1.5×ULN, ALT and AST ≤ 3.0×ULN (without liver metastases), ALT and AST ≤ 5.0×ULN (with liver metastases), Serum Creatinine ≤ 1×ULN, Endogenous Creatinine Clearance\>60ml/min~* Be able to read, understand and complete the questionnaire and diary~* Be able to understand the study procedures and sign informed consent.~Exclusion Criteria:~* Treatment with any other study medicine within 4 weeks before enrollment.~* Nausea or vomiting ≤ 24 hours prior to registration~* Ongoing emesis due to obstruction of digestive tract~* Concurrent use of olanzapine, phenothiazine or amifostine~* Female with pregnancy or lactation~* Severe cognitive compromise~* Known history of CNS disease (e.g. brain metastases, seizure disorder)~* Concurrent abdominal radiotherapy~* Chronic alcoholism~* Known hypersensitivity to aprepitant, tropisetron, or dexamethasone.~* Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months.~* History of uncontrolled diabetes mellitus~* Serious or uncontroled infection~* Known active HIV, viral hepatitis or tuberculosis infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant arm (Type: EXPERIMENTAL): Aprepitant + Tropisetron
- Control arm (Type: ACTIVE_COMPARATOR): Dexamethasone+ Tropisetron

Based on this trial design, predict the completion outcome and termination type (if applicable).